GSK

Deal terminate tear up end deal scrap
Biotech

GSK jilts Sosei, axing bowel disease drug amid immunology pivot

GSK backed out of the program, reportedly because of changes at its immunology unit, and returned rights to an IBD asset Sosei sees as a blockbuster.
Nick Paul Taylor Nov 27, 2023 5:00am
Merck Co headquarters

UPDATE: FDA AdComm votes against Merck's cough med

Nov 17, 2023 4:53pm
time minute

FDA skeptical of Merck's gefapixant, even after cough recount

Nov 16, 2023 11:00am
Jazz Pharmaceuticals

Jazz puts up $771M to form Autifony neuroscience discovery pact

Nov 14, 2023 9:40am
The silhouette of a miner digging

Hepatitis B drug developers chart slow progress, just like hep C

Nov 14, 2023 9:05am
garbage

Trio of biotechs toss programs to discard pile

Nov 9, 2023 11:23am